We first tested whether HODHBt enhanced the ability of IL-15-activated NK cells to kill the erythroleukemia K562 cell line, which lacks major histocompatibility complex (MHC) class I, making these cells a target for NK cells (48). The gene discussed is IL15; the disease is erythroleukemia.